Kyran Graham-Schmidt

1

Article

87

Comments
Excess dopamine activity is not the only neurological change seen in patients with schizophrenia. Image from shutterstock.com

Why we shouldn’t ditch the quest for new schizophrenia drugs

Matthew Anthony, Curtin University; Kyran Graham-Schmidt, The University of Western Australia, and Mathew Martin-Iverson, The University of Western Australia

The landscape of pharmaceutical development for mental disorders has changed over recent years, with pharma companies abandoning traditional neuroscience drug discovery programs and turning instead to…
  • Location: Perth, Western Australia
  • Article Feed
  • ORCID
  • Joined